Alzheimer disease and aducanumab: adjusting our approach

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059

Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance

Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002156 · Cited by 1,242

Microglial signatures and their role in health and disease

Butovsky, O., & Weiner, H. L. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0057-5 · Cited by 1,046

The A4 Study: Stopping AD Before Symptoms Begin?

Sperling, R. A., Rentz, D. M., Johnson, K. A., Karlawish, J. H., Donohue, M., Salmon, D. P., & Aisen, P. S. S. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007941 · Cited by 778

Preventing Alzheimer’s Disease

Selkoe, D. J. (2012) · Science · doi:10.1126/science.1228541 · Cited by 391

Alzheimer Disease: An Update on Pathobiology and Treatment Strategies

Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204

Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer’s Disease, Parkinson’s Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis

Nguyen, P. H., Ramamoorthy, A., Sahoo, B. R., Zheng, J., Faller, P., Straub, J. E., Domínguez, L., Shea, J., Dokholyan, N. V., Simone, A. D., et al. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01122 · Cited by 680

Function and therapeutic value of astrocytes in neurological diseases

Lee, H.-G., Wheeler, M. A., & Quintana, F. J. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00390-x · Cited by 662

Alzheimer’s disease: Recent treatment strategies

Vaz, M., & Silvestre, S. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173554 · Cited by 547

Alzheimer’s disease and its treatment by different approaches: A review

Srivastava, S., Ahmad, R., & Khare, S. K. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113320 · Cited by 506

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease

Palmqvist, S., Insel, P. S., Stomrud, E., Janelidze, S., Zetterberg, H., Brix, B., Eichenlaub, U., Dage, J. L., Chai, X., Blennow, K., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201911170 · Cited by 353

The Pivotal Role of NF-kB in the Pathogenesis and Therapeutics of Alzheimer’s Disease

Sun, E., Motolani, A., Campos, L., & Lu, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23168972 · Cited by 381

Cognitive symptoms of Alzheimer’s disease: clinical management and prevention

Joe, E., & Ringman, J. M. (2019) · BMJ · doi:10.1136/bmj.l6217 · Cited by 339

Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer’s disease: a systematic review

Jeremic, D., Jiménez-Díaz, L., & Navarro-López, J. D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101496 · Cited by 306

Iron dyshomeostasis, lipid peroxidation and perturbed expression of cystine/glutamate antiporter in Alzheimer’s disease: Evidence of ferroptosis

Ashraf, A., Jeandriens, J., Parkes, H. G., & So, P. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101494 · Cited by 306

The amyloid cascade hypothesis: an updated critical review

Kepp, K. P., Robakis, N. K. R. K., Høilund‐Carlsen, P. F., Sensi, S. L., & Vissel, B. (2023) · Brain · doi:10.1093/brain/awad159 · Cited by 315

Exosomes derived from bone-marrow mesenchymal stem cells alleviate cognitive decline in AD-like mice by improving BDNF-related neuropathology

Liu, S., Fan, M., Xu, J.-X., Yang, L.-J., Qi, C.-C., Xia, Q.-R., & Ge, J.-F. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02393-2 · Cited by 296

Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond

Song, C., Shi, J., Zhang, P., Zhang, Y., Xu, J., Zhao, L., Zhang, R., Wang, H., & Chen, H. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00292-3 · Cited by 266

Reasons for failed trials of disease-modifying treatments for alzheimer disease and their contribution in recent research

Yiannopoulou, K. G., Anastasiou, A. I., Zachariou, V., & Pelidou, S.-H. (2019) · Biomedicines · doi:10.3390/biomedicines7040097 · Cited by 330

Inhibition of miR-331-3p and miR-9-5p ameliorates Alzheimer's disease by enhancing autophagy

Chen, M., Hong, C., Yue, T., Li, H., Duan, R., Hu, W., Cao, J., Wang, Z., Chen, C., Hu, X., et al. (2020) · Theranostics · doi:10.7150/thno.47408 · Cited by 168

Amyloid β-protein and beyond: the path forward in Alzheimer’s disease

Walsh, D. M., & Selkoe, D. J. (2020) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2020.02.003 · Cited by 164

Passive immunotherapies targeting Aβ and tau in Alzheimer's disease

Plotkin, S. S., & Cashman, N. R. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105010 · Cited by 161

Depression as a Risk Factor for Alzheimer’s Disease: A Systematic Review of Longitudinal Meta-Analyses

Saiz-Vázquez, O., Gracia‐García, P., Landa, S. U., Puente-Martínez, A., Yusta, S. C., Olaya, B., & Santabárbara, J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10091809 · Cited by 165

Biomarkers used in Alzheimer’s disease diagnosis, treatment, and prevention

Mahaman, Y. A. R., Embaye, K. S., Huang, F., Li, L., Zhu, F., Wang, J.-Z., Liu, R., Feng, J., & Wang, X. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101544 · Cited by 149

Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease

Withington, C., & Turner, R. S. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.862369 · Cited by 158

Amyloid-β: a potential link between epilepsy and cognitive decline

Romoli, M., Sen, A., Parnetti, L., Calabresi, P., & Costa, C. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00505-9 · Cited by 133

Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer’s disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial.

Burns, D. K., Alexander, R. C., Welsh-Bohmer, K. A., Culp, M., Chiang, C., O’Neil, J., Evans, R. M., Harrigan, P., Plassman, B. L., Burke, J. R., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00043-0 · Cited by 130

Revisiting the Amyloid Cascade Hypothesis: From Anti-Aβ Therapeutics to Auspicious New Ways for Alzheimer’s Disease

Uddin, M. S., Kabir, M. T., Rahman, M. S., Behl, T., Jeandet, P., Ashraf, G. M., Najda, A., Bin-Jumah, M. N., El-Seedi, H. R., & Abdel‐Daim, M. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165858 · Cited by 131

Early diagnosis and treatment of Alzheimer’s disease: new definitions and challenges

Pais, M. V., Martinez, L. D., Ribeiro, O. G., Loureiro, J. C., Fernandez, R., Valiengo, L. D. C. L., Canineu, P. R., Stella, F., Talib, L. L., Radanovic, M., et al. (2020) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2019-0735 · Cited by 124

New therapeutics beyond amyloid-β and tau for the treatment of Alzheimer’s disease

Zhang, F., Zhong, R.-J., Cheng, C., Li, S., & Le, W.-D. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00565-5 · Cited by 105

Alzheimer’s disease beyond amyloid: Can the repetitive failures of amyloid-targeted therapeutics inform future approaches to dementia drug discovery?

Mullane, K., & Williams, M. J. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113945 · Cited by 109

Reduced secretion of LCN2 (lipocalin 2) from reactive astrocytes through autophagic and proteasomal regulation alleviates inflammatory stress and neuronal damage

Jung, B.-K., Park, Y., Yoon, B., Bae, J.-S., Han, S.-W., Heo, J. E., Kim, D., & Ryu, K. (2023) · Autophagy · doi:10.1080/15548627.2023.2180202 · Cited by 110

Immunotherapies for Aging-Related Neurodegenerative Diseases—Emerging Perspectives and New Targets

Kwon, S., Iba, M., Kim, C., & Masliah, E. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00853-2 · Cited by 97

Is tau in the absence of amyloid on the Alzheimer’s continuum?: A study of discordant PET positivity

Weigand, A. J., Bangen, K. J., Thomas, K. R., Delano‐Wood, L., Gilbert, P. E., Brickman, A. M., Bondi, M. W., & Initiative, A. D. N. (2019) · Brain Communications · doi:10.1093/braincomms/fcz046 · Cited by 93

Iron Dysregulation in Mitochondrial Dysfunction and Alzheimer’s Disease

Onukwufor, J. O., Dirksen, R. T., & Wojtovich, A. P. (2022) · Antioxidants · doi:10.3390/antiox11040692 · Cited by 85

Bridging the divide between biomedical and psychosocial approaches in dementia research: the 2019 INTERDEM manifesto

Vernooij-Dassen, M., Moniz-Cook, E., Verhey, F., Chattat, R., Woods, B., Meiland, F., Franco, M., Holmerova, I., Orrell, M., & de Vugt, M. (2021) · Aging & Mental Health · doi:10.1080/13607863.2019.1693968 · Cited by 80

Diabetes and Alzheimer’s Disease: Might Mitochondrial Dysfunction Help Deciphering the Common Path?

Potenza, M. A., Sgarra, L., Desantis, V., Nacci, C., & Montagnani, M. (2021) · Antioxidants · doi:10.3390/antiox10081257 · Cited by 78

Aducanumab—Hope or Disappointment for Alzheimer’s Disease

Wojtunik-Kulesza, K., Rudkowska, M., & Orzeł-Sajdłowska, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054367 · Cited by 73

Pharmacotherapy of Alzheimer’s Disease: Seeking Clarity in a Time of Uncertainty

Ibrahim, N. H., Yahaya, M. F., Mohamed, W. M. Y., Teoh, S. L., Hui, C. K., & Kumar, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00261 · Cited by 77

Therapy for Alzheimer’s disease: Missing targets and functional markers?

Stoiljković, M., Horváth, T. L., & Hajós, M. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101318 · Cited by 74

Actin-mediated Microglial Chemotaxis via G-Protein Coupled Purinergic Receptor in Alzheimer’s Disease

Das, R. R., & Chinnathambi, S. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.09.024 · Cited by 71

The Role of P2X7 Receptor in Alzheimer’s Disease

Francistiová, L., Bianchi, C., Lauro, C. D., Sebastián‐Serrano, Á., de Diego-García, L., Kobolák, J., Dinnyés, A., & Díaz-Hernández, M. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00094 · Cited by 73

Immunotherapy in Parkinson’s disease: Current status and future directions

Chatterjee, D., & Kordower, J. H. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104587 · Cited by 74

Hippocampal Deficits in Amyloid-β-Related Rodent Models of Alzheimer’s Disease

Vyas, Y., Montgomery, J. M., & Cheyne, J. E. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00266 · Cited by 66

RTN4B‐mediated suppression of Sirtuin 2 activity ameliorates β‐amyloid pathology and cognitive impairment in Alzheimer's disease mouse model

Wang, Y., Yang, J., Hong, T.-T., Sun, Y., Huang, H., Chen, F., Chen, X., Chen, H., Dong, S., Cui, L., et al. (2020) · Aging Cell · doi:10.1111/acel.13194 · Cited by 62

The future of stem cell therapies of Alzheimer’s disease

Wang, Z., Wang, Z.-T., Sun, Y., Tan, L., & Yu, J. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101655 · Cited by 65

Monoclonal Antibodies as Neurological Therapeutics

Gklinos, P., Papadopoulou, M., Stanulović, V., Mitsikostas, D. D., & Papadopoulos, D. (2021) · Pharmaceuticals · doi:10.3390/ph14020092 · Cited by 65

Functional and Phenotypic Diversity of Microglia: Implication for Microglia-Based Therapies for Alzheimer’s Disease

Xu, Y., Au, N. P. B., & Ma, C. H. E. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.896852 · Cited by 68

Increased plasma bradykinin level is associated with cognitive impairment in Alzheimer's patients

Singh, P. K., Chen, Z., Ghosh, D., Strickland, S., & Norris, E. H. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104833 · Cited by 58

Physiological Roles of Monomeric Amyloid-β and Implications for Alzheimer’s Disease Therapeutics

Jeong, H., Shin, H., Hong, S., & Kim, Y. S. (2022) · Experimental Neurobiology · doi:10.5607/en22004 · Cited by 59

Ferroptosis Is Regulated by Mitochondria in Neurodegenerative Diseases

Zhou, J.-P., Jin, Y., Lei, Y.-H., Liu, T., Wan, Z., Meng, H., & Wang, H. (2020) · Neurodegenerative Diseases · doi:10.1159/000510083 · Cited by 57

Targeting increased levels of APP in Down syndrome: Posiphen‐mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model

Chen, X., Salehi, A., Pearn, M. L., Overk, C., Nguyen, P. D., Kleschevnikov, A. M., Maccecchini, M. L., & Mobley, W. C. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12185 · Cited by 55

Cognitive load associates prolonged P300 latency during target stimulus processing in individuals with mild cognitive impairment

Demirayak, P., Kıyı, İ., Özbek, Y., & Yener, G. (2023) · Scientific Reports · doi:10.1038/s41598-023-43132-8 · Cited by 54

Promoting Alzheimer’s disease research and therapy with stem cell technology

Cao, Z., Kong, F., Ding, J., Chen, C., He, F., & Deng, W. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03737-w · Cited by 60

Drug delivery strategies with lipid-based nanoparticles for Alzheimer’s disease treatment

Jang, Y.-J., Kang, S.-J., Park, H. S., Lee, D., Kim, J. H., Kim, J.-E., Kim, D., Chung, C., Yoon, J., & Bhang, S. H. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03109-3 · Cited by 64

Effects of pharmacological modulators of α-synuclein and tau aggregation and internalization

Dominguez‐Meijide, A., Vasili, E., König, A., Cima‐Omori, M., de Opakua, A. I., Leonov, A., Ryazanov, S., Zweckstetter, M., Griesinger, C., & Outeiro, T. F. (2020) · Scientific Reports · doi:10.1038/s41598-020-69744-y · Cited by 52

Renin-Angiotensin System and Alzheimer’s Disease Pathophysiology: From the Potential Interactions to Therapeutic Perspectives

Ribeiro, V. T., de Souza, L. C., & Silva, A. C. S. E. (2019) · Protein and Peptide Letters · doi:10.2174/0929866527666191230103739 · Cited by 50

Pharmacotherapy of Alzheimer’s disease: an overview of systematic reviews

Majidazar, R., Rezazadeh‐Gavgani, E., Sadigh‐Eteghad, S., & Naseri, A. (2022) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-022-03363-6 · Cited by 54

Characterization and preclinical evaluation of the cGMP grade DNA based vaccine, AV-1959D to enter the first-in-human clinical trials

Petrushina, I., Hovakimyan, A., Harahap-Carrillo, I. S., Davtyan, H., Antonyan, T., Chailyan, G., Kazarian, K., Antonenko, M., Jullienne, A., Hamer, M. M., et al. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104823 · Cited by 48

Mutual population-shift driven antibody-peptide binding elucidated by molecular dynamics simulations

Bekker, G., Fukuda, I., Higo, J., & Kamiya, N. (2020) · Scientific Reports · doi:10.1038/s41598-020-58320-z · Cited by 48

Transferrin-Pep63-liposomes accelerate the clearance of Aβ and rescue impaired synaptic plasticity in early Alzheimer’s disease models

Yang, X., Xu, L., Le, L., Chen, Y.-H., You, Y., Gao, Y., Liu, Y., Yang, L., Tong, K., Chen, D., et al. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00639-1 · Cited by 46

Association of CSF Aβ 38 Levels With Risk of Alzheimer Disease–Related Decline

Cullen, N., Janelidze, S., Palmqvist, S., Stomrud, E., Mattsson, N., Hansson, O., & Initiative, A. D. N. (2021) · Neurology · doi:10.1212/wnl.0000000000013228 · Cited by 47

Targeting Hsc70-based autophagy to eliminate amyloid β oligomers

Dou, J., Su, P., Xu, C., Wen, Z., Mao, Z., & Li, W. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.02.016 · Cited by 46

Alzheimer’s disease, neural stem cells and neurogenesis: cellular phase at single-cell level

Kızıl, Ç., Coşacak, M. İ., & Bhattarai, P. (2019) · Neural Regeneration Research · doi:10.4103/1673-5374.268896 · Cited by 46

Neuroinflammation in Alzheimer's disease and beneficial action of luteolin

Delgado, A., Cholevas, C., & Theoharides, T. C. (2021) · BioFactors · doi:10.1002/biof.1714 · Cited by 48

Regulation of beta-amyloid production in neurons by astrocyte-derived cholesterolPreprint

Wang, H., Kulas, J. A., Ferris, H. A., & Hansen, S. B. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.18.159632 · Cited by 43

Passive Immunotherapies Targeting Amyloid Beta and Tau Oligomers in Alzheimer’s Disease

Zanden, C. M. V., & Chi, E. Y. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.10.024 · Cited by 40

Decoding metabolic signatures in Alzheimer’s disease: a mitochondrial perspective

Bano, D., Ehninger, D., & Bagetta, G. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01732-3 · Cited by 41

Testing a MultiTEP-based combination vaccine to reduce Aβ and tau pathology in Tau22/5xFAD bigenic mice

Davtyan, H., Hovakimyan, A., Kiani Shabestari, S., Antonyan, T., Coburn, M. A., Zagorski, K., Chailyan, G., Petrushina, I., Svystun, O., Danhash, E., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0556-2 · Cited by 37

Novel Therapeutic Strategies in Alzheimer’s Disease: Pitfalls and Challenges of Anti-Amyloid Therapies and Beyond

Tondo, G., Marchi, F. D., Bonardi, F., Menegon, F., Verrini, G., Aprile, D., Anselmi, M., Mazzini, L., & Comi, C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13113098 · Cited by 45

N‐terminal heterogeneity of parenchymal and vascular amyloid‐β deposits in Alzheimer’s disease

Zampar, S., Klafki, H., Sritharen, K., Bayer, T. A., Wiltfang, J., Rostagno, A. A., Ghiso, J. A., Miles, L. A., & Wirths, O. (2020) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12637 · Cited by 36

Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?

Silvestro, S., Valeri, A., & Mazzon, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042011 · Cited by 37

Rationale for the development of an Alzheimer’s disease vaccine

Kwan, P., Konno, H., Chan, K. Y., & Baum, L. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1665453 · Cited by 35

Undetectable gadolinium brain retention in individuals with an age‐dependent blood‐brain barrier breakdown in the hippocampus and mild cognitive impairment

Montagne, A., Huuskonen, M. T., Rajagopal, G., Sweeney, M. D., Nation, D. A., Sepehrband, F., D’Orazio, L. M., Harrington, M. G., Chui, H. C., Law, M., et al. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.07.012 · Cited by 33

Alzheimers Disease: New Concepts on the Role of Autoimmunity and NLRP3 Inflammasome in the Pathogenesis of the Disease

Severini, C., Barbato, C., Certo, M. G. D., Gabanella, F., Petrella, C., Stadio, A. D., VINCENTIIS, M. D., Polimeni, A., Ralli, M., & Greco, A. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200621204546 · Cited by 34

Plasmonic nanoparticle amyloid corona for screening Aβ oligomeric aggregate-degrading drugs

Lee, D., Park, D., Kim, I., Lee, S. W., Lee, W., Hwang, K. S., Lee, J. H., Lee, G., & Yoon, D. S. (2021) · Nature Communications · doi:10.1038/s41467-020-20611-4 · Cited by 33

Photobiomodulation in Alzheimer’s Disease—A Complementary Method to State-of-the-Art Pharmaceutical Formulations and Nanomedicine?

Ailioaie, L. M., Ailioaie, C., & Litscher, G. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030916 · Cited by 40

Casein Kinase 1 and Human Disease: Insights From the Circadian Phosphoswitch

Francisco, J. C., & Virshup, D. M. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.911764 · Cited by 30

Association between periodontitis and Alzheimer's disease: A narrative review

Seyedmoalemi, M., & Saied‐Moallemi, Z. (2025) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2024.12.004 · Cited by 29

Advances in Drug Therapy for Alzheimer’s Disease

Zhu, C.-C., Fu, S., Chen, Y., Li, L., Mao, R., Wang, J., Liu, R., Liu, Y., & Wang, X. (2020) · Current Medical Science · doi:10.1007/s11596-020-2281-2 · Cited by 34

Cerebrovascular amyloid Angiopathy in bioengineered vessels is reduced by high-density lipoprotein particles enriched in Apolipoprotein E

Robert, J., Button, E. B., Martin, E. M., McAlary, L., Gidden, Z., Gilmour, M., Boyce, G., Caffrey, T. M., Agbay, A., Clark, A., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00366-8 · Cited by 27

Application of 89Zr-DFO*-immuno-PET to assess improved target engagement of a bispecific anti-amyloid-ß monoclonal antibody

Stergiou, N., Wuensche, T. E., Schreurs, M., Mes, I., Verlaan, M., Kooijman, E. J. M., Windhorst, A. D., Helboe, L., Vergo, S. B., Christensen, S., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06109-3 · Cited by 27

Tumour necrosis factor induces increased production of extracellular amyloid-β- and α-synuclein-containing aggregates by human Alzheimer’s disease neurons

Whiten, D. R., Brownjohn, P. W., Moore, S., De, S., Strano, A., Zuo, Y., Haneklaus, M., Klenerman, D., & Livesey, F. J. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa146 · Cited by 28

Drug Discovery and Development Targeting Dementia

Zagórska, A., Czopek, A., Fryc, M., Jaromin, A., & Boyd, B. J. (2023) · Pharmaceuticals · doi:10.3390/ph16020151 · Cited by 29

Alzheimer Disease Clinical Trials Targeting Amyloid

Reiss, A. B., Montufar, N., DeLeon, J. R., Pinkhasov, A., Gomolin, I. H., Glass, A. D., Arain, H. A., & Stecker, M. M. (2021) · The Neurologist · doi:10.1097/nrl.0000000000000320 · Cited by 27

Operationalising fairness in medical AI adoption: detection of early Alzheimer’s disease with 2D CNN

Heising, L. M., & Angelopoulos, S. P. (2022) · BMJ Health & Care Informatics · doi:10.1136/bmjhci-2021-100485 · Cited by 28

Moringa Oleifera Alleviates Aβ Burden and Improves Synaptic Plasticity and Cognitive Impairments in APP/PS1 Mice

Mahaman, Y. A. R., Feng, J., Huang, F., Salissou, M. T. M., Wang, J., Liu, R., Zhang, B., Li, H., Zhu, F., & Wang, X. (2022) · Nutrients · doi:10.3390/nu14204284 · Cited by 31

Ferroptosis: a potential therapeutic target for Alzheimer’s disease

Yang, L., & Nao, J. (2022) · Reviews in the Neurosciences · doi:10.1515/revneuro-2022-0121 · Cited by 28

Emergence of distinct and heterogeneous strains of amyloid beta with advanced Alzheimer’s disease pathology in Down syndrome

Maxwell, A. M., Yuan, P., Rivera, B. M., Schaaf, W., Mladinov, M., Prasher, V. P., Robinson, A. C., DeGrado, W. F., & Condello, C. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01298-0 · Cited by 23

Approved drugs and natural products at clinical stages for treating Alzheimer’s disease

Ma, Y., Liu, S., Zhou, Q., Zhong-hua, L., ZHANG, Z., & Yu, B. (2024) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(24)60606-0 · Cited by 27

From monomer to fibril: Abeta‐amyloid binding to Aducanumab antibody studied by molecular dynamics simulation

Frost, C. V., & Zacharias, M. (2020) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.25978 · Cited by 25

Insight into the Double-Edged Role of Ferroptosis in Disease

Zhang, L., Jia, R., Li, H., Yu, H., Ren, K., Jia, S., Li, Y., & Wang, Q. (2021) · Biomolecules · doi:10.3390/biom11121790 · Cited by 26

A MultiTEP platform-based epitope vaccine targeting the phosphatase activating domain (PAD) of tau: therapeutic efficacy in PS19 mice

Hovakimyan, A., Antonyan, T., Shabestari, S. K., Svystun, O., Chailyan, G., Coburn, M., Carlen-Jones, W., Petrushina, I., Chadarevian, J. P., Zagorski, K., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-51809-2 · Cited by 27

Novel Biomarkers of Alzheimer's Disease: Based Upon N-methyl-D-aspartate Receptor Hypoactivation and Oxidative Stress

Chiang, T.-I., Yu, Y., Lin, C., & Lane, H. (2021) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2021.19.3.423 · Cited by 26

The Potential Emergence of Disease-Modifying Treatments for Alzheimer Disease: The Role of Primary Care in Managing the Patient Journey

Lam, J., Hlávka, J. P., & Mattke, S. (2019) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2019.06.180328 · Cited by 24

The Use of Patient-Derived Induced Pluripotent Stem Cells for Alzheimer’s Disease Modeling

Lee, C., Willerth, S. M., & Nygaard, H. B. (2020) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101804 · Cited by 24

Computational Investigation of Gantenerumab and Crenezumab Recognition of Aβ Fibrils in Alzheimer’s Disease Brain Tissue

Chen, Y., Wei, G., Zhao, J., Nussinov, R., & Ma, B. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00364 · Cited by 23

A single-domain antibody detects and neutralises toxic Aβ42 oligomers in the Alzheimer’s disease CSF

Bigi, A., Napolitano, L., Vadukul, D. M., Chiti, F., Cecchi, C., Aprile, F. A., & Cascella, R. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01361-z · Cited by 23

Single-cell-led drug repurposing for Alzheimer’s disease

Parolo, S., Mariotti, F., Bora, P., Carboni, L., & Domenici, E. (2023) · Scientific Reports · doi:10.1038/s41598-023-27420-x · Cited by 27

The Major Hypotheses of Alzheimer’s Disease: Related Nanotechnology-Based Approaches for Its Diagnosis and Treatment

Cáceres, C., Heusser, B., Garnham, A., & Moczko, E. (2023) · Cells · doi:10.3390/cells12232669 · Cited by 26

Targeting amyloid-β pathology by chimeric antigen receptor astrocyte (CAR-A) therapy

Chen, Y., Liu, Y. A., Nguyen, K. M., Wu, J., Song, S., Lin, K., Rodrigues, P. F., Du, S., Zhou, C., Xiong, K., et al. (2026) · Science · doi:10.1126/science.ads3972 · Cited by 28

SPG302 Reverses Synaptic and Cognitive Deficits Without Altering Amyloid or Tau Pathology in a Transgenic Model of Alzheimer's Disease

Trujillo‐Estrada, L., Vanderklish, P. W., Nguyen, M. M. T., Kuang, R. R., Nguyen, C., Huynh, E., da Cunha, C., Javonillo, D. I., Forner, S., Martini, A. C., et al. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01143-1 · Cited by 22

Resveratrol ameliorates learning and memory impairments induced by bilateral hippocampal injection of streptozotocin in mice

Wei, Y.-D., Chen, X.-X., Yang, L., Gao, X., Xia, Q., Qi, C., & Ge, J. (2022) · Neurochemistry International · doi:10.1016/j.neuint.2022.105385 · Cited by 23

Longitudinal evaluation of neuroinflammation and oxidative stress in a mouse model of Alzheimer disease using positron emission tomography

Rejc, L., Gómez‐Vallejo, V., Joya, A., Arsequell, G., Egimendia, A., Castellnou, P., Ríos, X., Cossío, U., Baz, Z., Iglesias, L., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01016-5 · Cited by 21

Repurposing non-pharmacological interventions for Alzheimer's disease through link prediction on biomedical literature

Xiao, Y., Hou, Y., Zhou, H., Diallo, G., Marcelo Fiszman, B., Wolfson, J. A., Zhou, L., Halil Kilicoglu, B., Chen, Y., Su, C., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-58604-8 · Cited by 25

Alzheimer’s immunotherapy: β-amyloid aggregates come unstuck

Martin, I. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aah7027

Anti-Aβ antibody treatment shows promise in Alzheimer disease

Fyfe, I. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.144 · Cited by 1

Beyond amyloid: New approaches to Alzheimer's disease treatment

(2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102648 · Cited by 3

Therapeutic news in Alzheimer’s disease: Soon a disease-modifying therapy?

Villain, N. (2022) · Revue Neurologique · doi:10.1016/j.neurol.2022.02.456 · Cited by 14

“Aducanumab” making a comeback in Alzheimer’s disease: An old wine in a new bottle

Behl, T., Kaur, I., Sehgal, A., Singh, S., Sharma, N., Makeen, H. A., Albratty, M., Alhazmi, H. A., Felemban, S. G., Alsubayiel, A. M., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112746 · Cited by 50